Literature DB >> 26905077

MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer.

Giulia Maria Stella1, Rebecca Senetta1, Simona Inghilleri1, Ludovica Verdun di Cantogno1, Cristina Mantovani1, Davide Piloni1, Luigia Scudeller1, Federica Meloni1, Mauro Papotti1, Umberto Ricardi1, Paola Cassoni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26905077      PMCID： PMC4799686          DOI： 10.1093/neuonc/nov325

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

1.  Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  G D'Addario; M Früh; M Reck; P Baumann; W Klepetko; E Felip
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

Review 2.  Liquid biopsy: monitoring cancer-genetics in the blood.

Authors:  Emily Crowley; Federica Di Nicolantonio; Fotios Loupakis; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2013-07-09       Impact factor: 66.675

3.  Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.

Authors:  Francesca De Bacco; Paolo Luraghi; Enzo Medico; Gigliola Reato; Flavia Girolami; Timothy Perera; Pietro Gabriele; Paolo M Comoglio; Carla Boccaccio
Journal:  J Natl Cancer Inst       Date:  2011-04-04       Impact factor: 13.506

Review 4.  MET signalling: principles and functions in development, organ regeneration and cancer.

Authors:  Livio Trusolino; Andrea Bertotti; Paolo M Comoglio
Journal:  Nat Rev Mol Cell Biol       Date:  2010-12       Impact factor: 94.444

Review 5.  Treatment of brain metastases from non-small-cell lung cancer (NSCLC): radiotherapy.

Authors:  Angelika Zabel; Jürgen Debus
Journal:  Lung Cancer       Date:  2004-08       Impact factor: 5.705

6.  MET mutations in cancers of unknown primary origin (CUPs).

Authors:  Giulia M Stella; Silvia Benvenuti; Daniela Gramaglia; Aldo Scarpa; Anna Tomezzoli; Paola Cassoni; Rebecca Senetta; Tiziana Venesio; Ernesto Pozzi; Alberto Bardelli; Paolo M Comoglio
Journal:  Hum Mutat       Date:  2010-11-09       Impact factor: 4.878

Review 7.  Drug development of MET inhibitors: targeting oncogene addiction and expedience.

Authors:  Paolo M Comoglio; Silvia Giordano; Livio Trusolino
Journal:  Nat Rev Drug Discov       Date:  2008-06       Impact factor: 84.694

8.  The role of surgical resection in patients with brain metastases.

Authors:  Mustafa Aziz Hatiboglu; David M Wildrick; Raymond Sawaya
Journal:  Ecancermedicalscience       Date:  2013-04-18
  8 in total
  5 in total

Review 1.  The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies.

Authors:  Alex Cazes; Betzaira G Childers; Edgar Esparza; Andrew M Lowy
Journal:  Cancers (Basel)       Date:  2022-04-18       Impact factor: 6.575

Review 2.  Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer.

Authors:  Giulia M Stella; Alessandra Gentile; Alice Balderacchi; Federica Meloni; Melissa Milan; Silvia Benvenuti
Journal:  J Transl Med       Date:  2016-09-02       Impact factor: 5.531

3.  RON tyrosine kinase mutations in brain metastases from lung cancer.

Authors:  Melissa Milan; Silvia Benvenuti; Alice Maria Balderacchi; Anna Rita Virzì; Alessandra Gentile; Rebecca Senetta; Paola Cassoni; Paolo Maria Comoglio; Giulia Maria Stella
Journal:  ERJ Open Res       Date:  2018-03-06

Review 4.  MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.

Authors:  Giulia M Stella; Silvia Benvenuti; Alessandra Gentile; Paolo M Comoglio
Journal:  EBioMedicine       Date:  2017-09-21       Impact factor: 8.143

Review 5.  A Need for More Molecular Profiling in Brain Metastases.

Authors:  Erica Shen; Amanda E D Van Swearingen; Meghan J Price; Ketan Bulsara; Roeland G W Verhaak; César Baëta; Brice D Painter; Zachary J Reitman; April K S Salama; Jeffrey M Clarke; Carey K Anders; Peter E Fecci; C Rory Goodwin; Kyle M Walsh
Journal:  Front Oncol       Date:  2022-01-25       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.